Therefore, screening patients for HLA alleles, particularly HLA-B*15:02, prior to initiating CBZ therapy may reduce the incidence and risk of CBZ-induced SJS-TEN and optimize treatment safety and efficacy in some populations. This evidence concerns the gene HLA-B and Schwartz-Jampel syndrome.